Therapeutic efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in North-Eastern Tanzania

Malaria Journal

Volumn 13, Issue 1, 2014, Pages

  Shayo, Alex ^a   Mandara, Celine I ^b   Shahada, Francis ^a   Buza, Joram ^a   Lemnge, Martha M ^b   Ishengoma, Deus S ^b  

^a NELSON MANDELA AFRICAN INSTITUTION OF SCIENCE AND TECHNOLOGY   (Tanzania)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

Author keywords

Artemether lumefantrine; Efficacy; Falciparum malaria; Safety; Tanzania

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; HEMOGLOBIN; ANTIMALARIAL AGENT; ARTEMETHER; ARTEMISININ DERIVATIVE; BENFLUMETOL; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE;

ABDOMINAL PAIN; ADEQUATE CLINICAL AND PARASITOLOGICAL RESPONSE; ADVERSE DRUG REACTION; ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CHILD; COUGHING; DIARRHEA; DISEASE SEVERITY; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG SAFETY; ENDEMIC DISEASE; FEMALE; FEVER; FOLLOW UP; GENOTYPE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; OUTCOME ASSESSMENT; PARASITEMIA; RASH; RECOMMENDED DRUG DOSE; TANZANIA; TREATMENT FAILURE; TREATMENT RESPONSE; UNCOMPLICATED FALCIPARUM MALARIA; WORLD HEALTH ORGANIZATION; CLINICAL TRIAL; DRUG COMBINATION; MALARIA, FALCIPARUM; PARASITOLOGY; PRESCHOOL CHILD; TREATMENT OUTCOME;

ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; FLUORENES; HUMANS; MALARIA, FALCIPARUM; MALE; TANZANIA; TREATMENT OUTCOME;

EID: 84908397452     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-13-376     Document Type: Article

References (46)

1. WHO: World Malaria Report. Geneva: World Health Organization; 2013.
2. WHO: Malaria control today: Current WHO recommendations. Geneva: World Health Organization; 2005.
3. Assefa A, Kassa M, Tadese G, Mohamed H, Animut A, Mengesha T: herapeutic efficacy of artemether/lumefantrine (Coartem) against Plasmodium falciparum in Kersa, South West Ethiopia. Parasit Vectors 2010, 3:1.
4. WHO: Global plan for artemisinin resistance containment (GPARC). Geneva: World Health Organization; 2011.
5. Okafor H, Nwaiwu O, Ukwandu N, Nmorsi O, Oyahkire G, Nwaosu S, Adebayo I, Kleinschmidt I, Omumbo J, Briet O: Monitoring antimalarial drug resistance within national malaria control programmes: the EANMAT experience. Trop Med Int Health 2001, 6:891-898.
6. MOH: National Guidelines for malaria diagnosis and treatment. United Republic of Tanzania: Ministry of Health; 2000.
7. MHSW: National Guidelines for malaria diagnosis and treatment. United Republic of Tanzania: National Malaria Control Programme Ministry of Health and Social Wellfare; 2006.
8. Kabanywanyi AM, Mwita A, Sumari D, Mandike R, Mugittu K, Abdulla S: Efficacy and safety of artemisinin-based antimalarial in the treatment of uncomplicated malaria in children in southern Tanzania. Malar J 2007, 6:146.
9. Kamugisha E, Jing S, Minde M, Kataraihya J, Kongola G, Kironde F, Swedberg G: Efficacy of artemether-lumefantrine in treatment of malaria among under-fives and prevalence of drug resistance markers in Igombe-Mwanza, north-western Tanzania. Malar J 2012, 11:58.
10. Ngasala BE, Malmberg M, Carlsson AM, Ferreira PE, Petzold MG, Blessborn D, Bergqvist Y, Gil JP, Premji Z, Björkman A: Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children < 5 years of age with acute uncomplicated Plasmodium falciparum malaria in rural Tanzania: a randomized trial. Clin Infect Dis 2011, 52:873-882.
11. Ngasala BE, Malmberg M, Carlsson AM, Ferreira PE, Petzold MG, Blessborn D, Bergqvist Y, Gil JP, Premji Z, Martensson A: Effectiveness of artemether-lumefantrine provided by community health workers in under-five children with uncomplicated malaria in rural Tanzania: an open label prospective study. Malar J 2011, 10:64.
12. WHO: Global Report on Antimalarial Drug Efficacy and Drug Resistance 2000-2010. Geneva: World Health Organization; 2010.
13. Mmbando BP, Vestergaard LS, Kitua AY, Lemnge MM, Theander TG, Lusingu JP: A progressive declining in the burden of malaria in north-eastern Tanzania. Malar J 2010, 9:216.
14. Poudel K, Okumura J, Sherchand J, Jimba M, Murakami I, Wahlstrom R, Kounnavong S, Sisounthone B, Phanyanouvong A, Southammavong T: The efficacy of antimalarial monotherapies sulphadoxine-pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy. Trop Med Int Health 2003, 8:860-867.
15. Clyde DF, Shute GT: Survival of pyrimethamine-resistant Plasmodium falciparum. Trans R Soc Trop Med Hyg 1959, 53:170-172.
16. Clyde DF: Drug resistance of malaria parasites in Tanzania. East Afr Med J 1966, 43:405-408.
17. Mutabingwa T, Nzila A, Mberu E, Nduati E, Winstanley P, Hills E, Watkins W: Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet 2001, 358:1218-1223.
18. Lemnge M, Alifrangis M, Kafuye MY, Gesase S, Minja D, Massaga J, Rønn A, Bygbjerg IC: High reinfection rate and treatment failures in children treated with amodiaquine for falciparum malaria in Muheza villages, Northeastern Tanzania. Am J Trop Med Hyg 2006, 75:188-193.
19. Mugittu K, Ndejembi M, Malisa A, Lemnge M, Premji Z, Mwita A, Nkya W, Kataraihya J, Abdulla S, Beck HP, Mshinda H: Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance. Am J Trop Med Hyg 2004, 71:696-702.
20. Gesase S, Gosling RD, Hashim R, Ord R, Naidoo I, Madebe R, Mosha JF, Joho A, Mandia V, Mrema H: High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at Codon 581. PLoS ONE 2009, 4:e4569.
21. Rønn AM, Msangeni H, Mhina J, Wernsdorfer W, Bygbjerg I: High level of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine in children in Tanzania. Trans R Soc Trop Med Hyg 1996, 90:179-181.
22. Alifrangis M, Lemnge MM, Ronn AM, Segeja MD, Magesa SM, Sukri N, Laras K, Wandra T, Didi S, Larasati R: Increasing prevalence of wildtypes in the dihydrofolate reductase gene of Plasmodium falciparum in an area with high levels of sulfadoxine/pyrimethamine resistance after introduction of treated bed nets. Am J Trop Med Hyg 2003, 69:238-243.
23. Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C, Greenwood BM, Whitty CJ: Amodiaquine alone, amodiaquine+ sulfadoxine-pyrimethamine, amodiaquine+ artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 2005, 365:1474-1480.
24. WHO: Methods for Surveillance of Antimalaria Drug efficacy. Geneva: World Health Organization; 2009.
25. Ishengoma DS, Mmbando BP, Segeja MD, Alifrangis M, Lemnge MM, Bygbjerg IC: Declining burden of malaria over two decades in a rural community of Muheza district, north-eastern Tanzania. Malar J 2013, 12:338.
26. WHO: Basic malaria microscopy, Part 1. Learner's guide, Second Edition. Geneva: Word Health Oraganization; 2010.
27. Venkatesan M, Amaratunga C, Campino S, Auburn S, Koch O, Lim P, Uk S, Socheat D, Kwiatkowski DP, Fairhurst RM: Using CF11 cellulose columns to inexpensively and effectively remove human DNA from Plasmodium falciparum-infected whole blood samples. Malar J 2012, 11:41.
28. Basco LK, Tahar R, Escalante A: Molecular epidemiology of malaria in Cameroon. XVIII. Polymorphisms of the Plasmodium falciparum merozoite surface antigen-2 gene in isolates from symptomatic patients. Am J Trop Med Hyg 2004, 70:238-244.
29. WHO: Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. Geneva: World Health Organization; 2008.
30. WHO: Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. Geneva: World Health Organization; 2003.
31. Clyde D, Shute G: Resistance of Plasmodium falciparum in Tanganyika to pyrimethamine administered at weekly intervals. Trans R Soc Trop Med Hyg 1957, 51:505-513.
32. Falade C, Makanga M, Premji Z, Ortmann C-E, Stockmeyer M, De Palacios PI: Efficacy and safety of artemether-lumefantrine (Coartem®) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 2005, 99:459-467.
33. Kefyalew T, Animut A, Tamene T, Jima D, Hailemariam A, Legesse M: Efficacy of six-dose regimen of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria, three years after its introduction into Ethiopia. Parasite 2009, 16:129-134.
34. Makanga M, Bassat Q, Falade CO, Premji ZG, Krudsood S, Hunt P, Walter V, Beck H-P, Marrast A-C, Cousin M: Efficacy and safety of artemether-lumefantrine in the treatment of acute, uncomplicated Plasmodium falciparum malaria: a pooled analysis. Am J Trop Med Hyg 2011, 85:793.
35. Makanga M, Premji Z, Falade C, Karbwang J, Mueller EA, Andriano K, Hunt P, De Palacios PI: Efficacy and safety of the six-dose regimen of artemether-lumefantrine in pediatrics with uncomplicated Plasmodium falciparum malaria: a pooled analysis of individual patient data. Am J Trop Med Hyg 2006, 74:991-998.
36. Valecha N, Srivastava P, Mohanty SS, Mittra P, Sharma SK, Tyagi PK, Pradhan K, Dev V, Singh R, Dash AP: Therapeutic efficacy of artemether-lumefantrine in uncomplicated falciparum malaria in India. Malar J 2009, 8:107.
37. Group FA-BCS: A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med 2011, 8:e1001119.
38. Kinfu G, Gebre-Selassie S, Fikrie N: Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum Malaria in Northern Ethiopia. Malar Res Treat 2012, 2012:548710.
39. Premji ZG: Coartem®: the journey to the clinic. Malar J 2009, 8(Suppl 1):S3.
40. O'dempsey T, McArdle T, Laurence B, Lamont A, Todd J, Greenwood B: Overlap in the clinical features of pneumonia and malaria in African children. Trans R Soc Trop Med Hyg 1993, 87:662-665.
41. Hatz C, Abdulla S, Mull R, Schellenberg D, Gathmann I, Kibatala P, Beck HP, Tanner M, Royce C: Efficacy and safety of CGP 56697 (artemether and benflumetol) compared with chloroquine to treat acute falciparum malaria in Tanzanian children aged 1-5 years. Trop Med Int Health 1998, 3:498-504.
42. Ghani AC, Sutherland CJ, Riley EM, Drakeley CJ, Griffin JT, Gosling RD, Filipe JA: Loss of population levels of immunity to malaria as a result of exposure-reducing interventions: consequences for interpretation of disease trends. PLoS ONE 2009, 4:e4383.
43. Winskill P, Rowland M, Mtove G, Malima RC, Kirby MJ: Malaria risk factors in north-east Tanzania. Malar J 2011, 10:98.
44. Lusingu J, Vestergaard L, Mmbando B, Drakeley C, Jones C, Akida J, Savaeli Z, Kitua A, Lemnge M, Theander T: Malaria morbidity and immunity among residents of villages with different Plasmodium falciparum transmission intensity in North-Eastern Tanzania. Malar J 2004, 3:26.
45. Rutta A, Francis F, Mmbando BP, Ishengoma DS, Sembuche SH, Malecela EK, Sadi JY, Kamugisha ML, Lemnge MM: Using community-owned resource persons to provide early diagnosis and treatment and estimate malaria burden at community level in north-eastern Tanzania. Malar J 2012, 11:152.
46. Enevold A, Nkya WM, Theisen M, Vestergaard LS, Jensen AT, Staalsoe T, Theander TG, Bygbjerg IC, Alifrangis M: Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum. Malar J 2007, 6:153.